Bristol-Myers Squibb said that the phase 3 study of its drug Zeposia to treat moderate to severe active Crohn's disease failed to reach the main clinical remission end in week 12.
Zhitong Finance learned that the Phase 3 study of its drug Zeposia to treat severe active Crohn's disease failed to reach the main clinical remission end in week 12, according to Zhitong Finance. The study is the first of two 12-week induction studies in the Yellowstone Phase 3 clinical trial. The company did not mention the progress of the second study in its statement. Zeposia, also known as ozanimod, has been approved by the FDA to treat multiple sclerosis and ulcerative colitis.